title: Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.
abstract: Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10-20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p less than 0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome.
authors: Istituto di Clinica Medica e Gastroenterologia, Università di Bologna, Italy.
authors: G A
authors: GA
authors: Lanfranchi
authors: G
authors: G
authors: Bazzocchi
authors: M
authors: M
authors: Campieri
authors: C
authors: C
authors: Brignola
authors: F
authors: F
authors: Fois
authors: B P
authors: BP
authors: Imbimbo
mesh_terms: D012809:Colon, Sigmoid / Q000503:physiopathology*; D003109:Colonic Diseases, Functional / Q000188:drug therapy / Q000503:physiopathology*; D003248:Constipation / Q000503:physiopathology; D004435:Eating; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D010276:Parasympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D012602:Scopolamine Derivatives / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C016859:cimetropium